<DOC>
	<DOCNO>NCT00003957</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy autologous peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient relapse non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Relapsed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine many patient chemotherapy sensitive relapse non-Hodgkin 's lymphoma receive sequential high dose chemotherapy achieve collection minimum 5 million CD34+ cells/kg one large volume apheresis . II . Determine feasibility safety regimen patient . III . Determine disease free overall survival patient receive regimen . OUTLINE : Patients receive cyclophosphamide IV 1 hour follow paclitaxel IV 24 hour day 1 . Filgrastim ( G-CSF ) stem cell factor ( SCF ) administer subcutaneously begin day 3 approximately 7-14 day ( completion leukapheresis ) . Peripheral blood stem cell ( PBSC ) collect 3-5 day . Three week leukapheresis complete , patient receive cytarabine IV 2 hour twice day day -6 -3 . Mitoxantrone IV administer 1 hour day -6 . CD34+ PBSC reinfused day 0 . Four week later , patient receive etoposide IV 11 hour day -2 melphalan IV 30 minute twice day -1 . CD34+ PBSC reinfused day 0 . Concurrent G-CSF administer subcutaneously continue blood count recover . Patients follow 4 week , every 3 month first 2 year , every 6 month next 2 year . PROJECTED ACCRUAL : A total 12 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular diffuse large cell , diffuse mixed , immunoblastic nonHodgkin 's lymphoma ( work formulation D , F , G , H ) First relapse complete response complete response unconfirmed front line chemotherapy regimen ( e.g. , CHOPlike regimen ) Second relapse partial response 24 course second line standard dose chemotherapy ( e.g. , MINE , EPOCH , platinumcontaining regimen ) No 1 salvage treatment regimen No CNS involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Transaminases great 2 time upper limit normal Bilirubin great 2 mg/dL ( unless due biopsy proven lymphoma ) No chronic viral hepatitis Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min No overt renal insufficiency Cardiovascular : LVEF least 45 % No congestive heart failure ( New York Heart Association class III IV ) No myocardial infarction within past 6 month No uncontrolled hypertension ( diastolic blood pressure great 115 mmHg ) No unstable angina No coronary angioplasty within past 6 month No uncontrolled atrial ventricular cardiac arrhythmia Pulmonary : DLCO FEV1 least 45 % predict No severe pulmonary disease No seasonal recurrent asthma within past 10 year No asthmatic symptom ( e.g. , wheeze ) relate current respiratory tract infection No concurrent symptom bronchoconstriction No anaphylactic/anaphylactoidtype event manifest disseminated urticaria , laryngeal edema , and/or bronchospasm Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No prior malignancy within past 5 year except carcinoma situ cervix basal cell squamous cell skin cancer No severe medical psychiatric illness ( include severe depression ) No active peptic ulcer disease No poorly control diabetes No allergy insect vemons No active history angioedema recurrent urticaria ( isolated episode urticaria allow ) No active infection No fever great 38.2 degree C ( except fever due B symptom ) No allergy E. coli derive product PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior hematopoietic growth factor Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy relapse site vital organ ( except part initial treatment ) At least 4 week since prior palliative radiotherapy bulky node Surgery : At least 2 week since prior major surgery Other : No concurrent investigational drug No concurrent beta adrenergic block agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
</DOC>